2022
Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus–Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy
Tsai CJ, McBride SM, Riaz N, Kang JJ, Spielsinger DJ, Waldenberg T, Gelblum D, Yu Y, Chen LC, Zakeri K, Wong RJ, Dunn L, Pfister DG, Sherman EJ, Lee NY. Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus–Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy. JAMA Oncology 2022, 8: 364-372. PMID: 35050342, PMCID: PMC8778604, DOI: 10.1001/jamaoncol.2021.6416.Peer-Reviewed Original ResearchConceptsDistant metastasis-free survivalProgression-free survivalMetastasis-free survivalOropharyngeal carcinomaConcurrent chemoradiotherapyDe-escalation strategiesRadiotherapy doseTotal doseSubclinical regionsLocoregional controlGross diseaseCohort studyOverall survivalClinical outcomesHuman Papillomavirus–Associated Oropharyngeal CarcinomaHigh-dose cisplatin therapyHPV-positive oropharyngeal carcinomaTarget volumeBilateral level IBGy of radiotherapyPrimary concurrent chemoradiotherapyRetrospective cohort studyFavorable clinical outcomeAmerican Joint CommitteeLong-term follow
2019
A retrospective analysis of cisplatin dosing strategies when used with radiation on outcomes in head and neck squamous cell carcinoma of the oropharynx.
Tchekmedyian V, Ho A, Dunn L, Fetten J, Pfister D, Lobaugh S, Zhang Z, Kang J, Chen L, Riaz N, McBride S, Yu Y, Tsai C, Lee N, Sherman E. A retrospective analysis of cisplatin dosing strategies when used with radiation on outcomes in head and neck squamous cell carcinoma of the oropharynx. Journal Of Clinical Oncology 2019, 37: 6079-6079. DOI: 10.1200/jco.2019.37.15_suppl.6079.Peer-Reviewed Original ResearchHPV/p16 statusOverall survivalRetrospective analysisTotal doseT stageP16 statusMultivariate Cox proportional hazards modelMultivariate analysisMedian f/uCox proportional hazards regressionCox proportional hazards modelNeck squamous cell carcinomaHPV/p16Start of RTProportional hazards regressionSquamous cell carcinomaSplit-dose administrationProportional hazards modelCI dosingPrimary CRTInduction chemotherapyCRT outcomesDistant failureProspective trialMedian age